Conatus Pharmaceuticals Files For IPO

San Diego-based Conatus Pharmaceuticals, which is developing treatments for liver disease, has filed for an IPO, saying this morning that it is looking to raised $69.0M on the public markets. The firm said plans to trade on the NASDAQ Global Market as CNAT. The IPO is being underwritten by Stifel, Piper Jaffray, JMP Securities, and SunTrust Robinson Humphrey. The firm is venture backed by Aberdare Ventures, Advent Private Equity, Cooperative Gilde Healthcare, MPM Capital, AgeChem Venture Fund, Roche, and others.